Scott
A. Ziegler, Esq.
|
Ziegler,
Ziegler & Associates LLP
570
Lexington Avenue, 44th
Floor
New
York, New York 10022
(212)
319-7600
|
ý immediately
upon filing
|
||
o on (Date)
at (Time)
|
Title
of each class of
Securities
to be registered
|
Amount
to
be registered
|
Proposed
maximum aggregate price per unit (1)
|
Proposed
maximum
aggregate
offering price (2)
|
Amount
of
registration
fee
|
American
Depositary Shares evidenced by American Depositary Receipts, each American
Depositary Share representing one ordinary share of AstraZeneca
PLC
|
50,000,000
American
Depositary Shares
|
$0.05
|
$2,500,000
|
$139.50
|
(1)
|
Each
unit represents one American Depositary
Share.
|
(2)
|
Estimated
solely for the purpose of calculating the registration
fee. Pursuant to Rule 457(k), such estimate is computed on
the basis of the maximum aggregate fees or charges to be imposed in
connection with the issuance of American Depositary Receipts evidencing
American Depositary Shares.
|
Item Number and Caption
|
Location
in Form of American Depositary
Receipt Filed Herewith as Prospectus
|
|||
(1) | Name and address of Depositary |
Introductory
paragraph and bottom of face of American Depositary
Receipt
|
||
(2) | Title of American Depositary Receipts and identity of deposited securities |
Face
of American Depositary Receipt, top center
|
||
Terms of Deposit: | ||||
(i) |
Amount
of deposited securities represented by one unit of American Depositary
Shares
|
Face
of American Depositary Receipt, upper right corner
|
||
(ii) |
Procedure
for voting, if any, the deposited securities
|
Paragraph
(12)
|
||
(iii) |
Collection
and distribution of dividends
|
Paragraphs
(4), (5), (7) and (10)
|
||
(iv) |
Transmission
of notices, reports and proxy soliciting material
|
Paragraphs
(3), (8) and (12)
|
||
(v) |
Sale
or exercise of rights
|
Paragraphs
(4), (5) and (10)
|
||
(vi) |
Deposit
or sale of securities resulting from dividends, splits or plans of
reorganization
|
Paragraphs
(4), (5), (10) and (13)
|
||
(vii) |
Amendment,
extension or termination of the Deposit Agreement
|
Paragraphs
(16) and (17)
|
||
(viii) |
Rights
of holders of ADRs to inspect the transfer books of the Depositary and the
list of Holders of ADRs
|
Paragraph
(3)
|
||
(ix) |
Restrictions
upon the right to deposit or withdraw the underlying
securities
|
Paragraphs
(1), (2), (4), and (5)
|
||
(x) |
Limitation
upon the liability of the Depositary
|
Paragraph
(14)
|
||
(3) | Fees and Charges |
Paragraph
(7)
|
Item Number and Caption |
Location
in Form of American Depositary
Receipt Filed Herewith as Prospectus |
|||
(b) | Statement that AstraZeneca PLC is subject to the periodic reporting requirements of the Securities Exchange Act of 1934, as amended, and, accordingly files certain reports with the Securities and Exchange Commission, and that such reports can be inspected by holders of American Depositary Receipts and copied at public reference facilities maintained by the Securities and Exchange Commission in Washington, D.C. |
Paragraph
(8)
|
|
(a)
|
Form of Deposit
Agreement. Form of Second Amended and Restated Deposit Agreement
among AstraZeneca PLC (the "Company"), JPMorgan Chase Bank, N.A. (fka
Morgan Guaranty Trust Company of New York), as depositary (the
"Depositary"), and all holders from time to time of ADRs issued thereunder
(the "Deposit Agreement"), including form of ADR. Filed
herewith as Exhibit (a)
|
|
(b)
|
Any other agreement to which
the Depositary is a party relating to the issuance of the American
Depositary Shares registered hereunder or the custody of the deposited
securities represented thereby. Not
Applicable.
|
|
(c)
|
Every material contract
relating to the deposited securities between the Depositary and the issuer
of the deposited securities in effect at any time within the last three
years. Not
Applicable.
|
|
(d)
|
Opinion of Ziegler, Ziegler
& Associates LLP, counsel to the Depositary, as to the legality of the
securities being registered. Filed herewith as Exhibit
(d).
|
|
(e)
|
Certification under Rule
466. Filed herewith as Exhibit
(e).
|
|
(f)
|
Power of
Attorney. Included as part of the signature pages
hereto.
|
|
(a)
|
The
Depositary hereby undertakes to make available at the principal office of
the Depositary in the United States, for inspection by holders of the
American Depositary Receipts, any reports and communications received from
the issuer of the deposited securities which are both (1) received by
the Depositary as the holder of the deposited securities, and
(2) made generally available to the holders of the underlying
securities by the issuer.
|
|
(b)
|
If
the amounts of fees charged are not disclosed in the prospectus, the
Depositary undertakes to prepare a separate document stating the amount of
any fee charged and describing the service for which it is charged and to
deliver promptly a copy of such fee schedule without charge to anyone upon
request. The Depositary undertakes to notify each registered
holder of an American Depositary Receipt thirty days before any change in
the fee schedule.
|
Legal
entity created by the form of Deposit Agreement for the issuance of ADRs
evidencing American Depositary
Shares
|
|||
By:
|
JPMorgan
Chase Bank, N.A., as Depositary
|
||
|
By:
|
/s/
Joseph M. Leinhauser
|
|
Name: | Joseph M. Leinhauser | ||
Title: | Vice President |
AstraZeneca
PLC
|
|||
|
By:
|
/s/
David Brennan
|
|
Name: | David Brennan | ||
Title: |
Chief
Executive Officer
|
Signature
|
Title
|
|
/s/Louis Schweitzer
|
Non-Executive
Chairman of the Board of Directors
|
|
Louis
Schweitzer
|
||
/s/David Brennan
|
Chief
Executive Officer and Executive Director
|
|
David
Brennan
|
||
/s/Simon Lowth
|
Chief
Financial Officer and Executive Director
|
|
Simon
Lowth
|
||
.
|
Non-Executive
Director
|
|
Jane
Henney
|
/s/Marcus Wallenberg
|
Non-Executive
Director
|
|
Marcus
Wallenberg
|
||
/s/Dame Nancy Rothwell
|
Non-Executive
Director
|
|
Dame
Nancy Rothwell
|
||
/s/Bo Angelin
|
Non-Executive
Director
|
|
Bo
Angelin
|
||
/s/Michele Hooper
|
Senior
Non-Executive Director
|
|
Michele
Hooper
|
||
.
|
Non-Executive
Director
|
|
John
Varley
|
||
/s/John Buchanan
|
Non-Executive
Director
|
|
John
Buchanan
|
||
/s/Jean-Philippe Courtois
|
Non-Executive
Director
|
|
Jean-Philippe
Courtois
|
||
/s/Rudy Markham
|
Non-Executive
Director
|
|
Rudy
Markham
|
|
|
/s/Glenn M. Engelmann
|
|
|
Glenn
M. Engelmann,
as duly authorized representative of AstraZeneca PLC in the United States |
Exhibit
Number |
|
(a)
|
Form
of Second Amended and Restated Deposit Agreement.
|
(d)
|
Opinion
of Ziegler, Ziegler & Associates LLP, counsel to the Depositary, as to
the legality of the securities to be registered.
|
(e)
|
Rule
466 Certification
|